GlassScriptPhysician profile
Damaso A Oliva
NPI 1659304350
$170,494.28
in general payments reported to CMS, 2019-2025
26 companies · $34K in 2025
The $34K reported for 2025 was more than what 97% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,510 · 2020: $4,085 · 2021: $16K · 2022: $32K · 2023: $39K · 2024: $41K · 2025: $34K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $63K · Consulting Fee: $27K · Food and Beverage: $18K · Travel and Lodging: $5,773 · Education: $73.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $63,338.00 |
| Consulting Fee | $26,759.00 |
| Food and Beverage | $18,121.37 |
| Travel and Lodging | $5,772.69 |
| Education | $73.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $71,600.54 | 2019-2025 | Ingrezza |
| Alkermes, INC. | $69,068.91 | 2019-2025 | Lybalvi, Aristada |
| Teva Pharmaceuticals USA, INC. | $4,924.88 | 2019-2025 | Austedo Xr, Uzedy, Austedo |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $4,323.45 | 2020-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $3,145.55 | 2019-2025 | Invega Sustenna, Invega Trinza |
| E.R. Squibb & Sons, L.L.C. | $3,079.35 | 2024-2025 | Cobenfy, Avapro |
| Otsuka America Pharmaceutical, INC. | $2,956.03 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Sunovion Pharmaceuticals INC. | $2,694.36 | 2019-2022 | |
| Lundbeck LLC | $1,600.94 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Abbvie INC. | $1,596.99 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $846.21 | 2019-2023 | Belsomra |
| Almatica Pharma LLC | $776.29 | 2022-2025 | Loreev Xr, Sertraline Hcl, Venlafaxine |
| Axsome Therapeutics, INC. | $713.38 | 2024-2025 | Auvelity, Sunosi |
| Takeda Pharmaceuticals U.S.A., INC. | $601.09 | 2020-2025 | Trintellix |
| Allergan, INC. | $556.14 | 2019-2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $448.29 | 2019-2025 | Fanapt, Hetlioz |
| Eisai INC. | $426.07 | 2020-2021 | |
| Alfasigma USA, INC. | $327.87 | 2020-2021 | |
| Idorsia Pharmaceuticals US INC | $225.60 | 2022-2024 | Quviviq |
| Noven Therapeutics, LLC | $146.41 | 2021 | |
| Corium, LLC | $110.46 | 2022-2023 | Adlarity |
| Avanir Pharmaceuticals, INC. | $101.26 | 2019-2020 | |
| Biogen, INC. | $81.49 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $61.92 | 2021-2022 | |
| Noven Pharmaceuticals, INC. | $44.29 | 2021 | |
| Luye Pharma (USA) LTD. | $36.51 | 2025 | Erzofri Extended-Release |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Damaso Oliva listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.